(0.32%) 5 116.17 points
(0.38%) 38 386 points
(0.35%) 15 983 points
(-0.01%) $82.62
(0.84%) $2.05
(-0.53%) $2 345.30
(-0.96%) $27.40
(-0.33%) $958.30
(0.06%) $0.933
(0.11%) $10.99
(-0.01%) $0.796
(0.01%) $93.31
-1.59% $ 0.806
Live Chart Being Loaded With Signals
Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology...
Stats | |
---|---|
Tagesvolumen | 45 778.00 |
Durchschnittsvolumen | 99 912.00 |
Marktkapitalisierung | 43.76M |
EPS | $0 ( 2024-03-14 ) |
Nächstes Ertragsdatum | ( $-0.120 ) 2024-05-07 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -1.260 |
ATR14 | $0.00700 (0.87%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-02 | Jones Edward Raymond | Buy | 22 000 | Stock Option (Right to Buy) |
2024-04-02 | Deliargyris Efthymios | Buy | 61 000 | Common Stock |
2024-04-02 | Deliargyris Efthymios | Buy | 86 000 | Stock Option (Right to Buy) |
2024-04-02 | Sobel Alan D. | Buy | 22 000 | Stock Option (Right to Buy) |
2024-04-02 | Bloch Kathleen P. | Buy | 65 000 | Common Stock |
INSIDER POWER |
---|
77.72 |
Last 100 transactions |
Buy: 4 191 625 | Sell: 429 500 |
Volumen Korrelation
Cytosorbents Corp Korrelation
10 Am meisten positiv korreliert | |
---|---|
PRQR | 0.959 |
KIN | 0.958 |
SRRA | 0.949 |
NLSP | 0.947 |
BTWNU | 0.943 |
PROF | 0.941 |
GENQ | 0.94 |
ALXN | 0.939 |
RILYH | 0.938 |
IDCC | 0.932 |
10 Am meisten negativ korreliert | |
---|---|
ZENV | -0.95 |
GRIN | -0.949 |
UTME | -0.948 |
NCBS | -0.945 |
THMA | -0.942 |
PDBC | -0.939 |
RIVN | -0.938 |
SNPX | -0.934 |
SOPA | -0.93 |
NAKD | -0.928 |
Wussten Sie das?
Korrelation ist ein statistisches Maß, das die Beziehung zwischen zwei Variablen beschreibt. Es reicht von -1 bis 1, wobei -1 eine perfekte negative Korrelation (wenn eine Variable zunimmt, nimmt die andere ab) anzeigt, 1 eine perfekte positive Korrelation (wenn eine Variable zunimmt, nimmt die andere zu) und 0 keine Korrelation anzeigt (es besteht kein Zusammenhang zwischen den Variablen).
Korrelation kann verwendet werden, um die Beziehung zwischen beliebigen zwei Variablen zu analysieren, nicht nur zwischen Aktien. Es wird häufig in Bereichen wie Finanzen, Wirtschaft, Psychologie und mehr verwendet.
Cytosorbents Corp Korrelation - Währung/Rohstoff
Cytosorbents Corp Finanzdaten
Annual | 2023 |
Umsatz: | $36.35M |
Bruttogewinn: | $22.39M (61.60 %) |
EPS: | $-0.640 |
FY | 2023 |
Umsatz: | $36.35M |
Bruttogewinn: | $22.39M (61.60 %) |
EPS: | $-0.640 |
FY | 2022 |
Umsatz: | $29.36M |
Bruttogewinn: | $15.40M (52.47 %) |
EPS: | $-0.750 |
FY | 2021 |
Umsatz: | $43.17M |
Bruttogewinn: | $32.12M (74.41 %) |
EPS: | $-0.570 |
Financial Reports:
No articles found.
Cytosorbents Corp
Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology. Its flagship product is CytoSorb, an extracorporeal cytokine filter for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention and treatment of perioperative complications of cardiopulmonary bypass surgery, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant. The company also develops VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals; CytoSorb-XL, a device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients, as well as removal of anti-A and anti-B blood group antibodies from fresh whole blood and plasma; K+ontrol for treatment of severe hyperkalemia in patients with life-threatening conditions; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. In addition, it is involved in the development of BetaSorb, a device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; DrugSorb, a device to remove toxic chemicals from the blood; and DrugSorb-ATR, an antithrombotic removal system. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey.
Über Live-Signale
Die Live-Signale auf dieser Seite helfen dabei zu bestimmen, wann man NA kaufen oder verkaufen soll. Die Signale haben eine Verzögerung von bis zu 1 Minute; wie bei allen Marktsignalen besteht die Möglichkeit von Fehlern oder Fehleinschätzungen.
Die Live-Handelssignale sind nicht endgültig und getagraph.com übernimmt keine Verantwortung für Maßnahmen, die aufgrund dieser Signale ergriffen werden, wie in den Nutzungsbedingungen beschrieben. Die Signale basieren auf einer breiten Palette von technischen Analyseindikatoren.